As reported by National Health Executive, the UK Health Security Agency (UKHSA) partners with the Office for National Statistics (ONS) for a major covid-19 study, using 32,000 weekly tests to assess the virus’s impact and hospitalization rates ahead of winter
ONS and UKHSA also collaborated on the coronavirus infection study which began just a month after the pandemic started and lasted until March 2023.
Recognised as the gold standard for surveillance of the virus, the study investigated over 11 million swab tests and three million blood tests.
“The data we collected alongside the ONS during the pandemic provided us with a huge amount of valuable insight, so I am delighted that we are able to work together again to keep policymakers and the wider public informed in the coming months,” said UKHSA’s director general of data, analytics and surveillance, Professor Steven Riley.
“UKHSA continues to lead the way internationally on COVID-19 surveillance and by re-introducing a study of positivity in the community, we can better detect changes in the behaviour of the virus.”
The news comes shortly after UKHSA announced the launch of its new dashboard to centralise all infectious disease and outbreak data ahead of winter.
WCIS will feature up to 200,000 participants and run from November 2023 to March 2024.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events relating to CSL Seqirus products should also be reported to Seqirus UK Limited on 01748 828816.
1. Seqirus Data on File, August 2023. SREF–17994. 2. Adjuvanted Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics. 3. Cell-based Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics.
Be the first to comment